Development of new technology for drug delivery to the dermis of the skin without skin damage
Feb 04, 2025
|
Through joint research with Agnes Medical (CEO Ahn Sung-yong), the Korea Institute of Electronics and Technology, and Korea University, the dermatology research team at Chung-Ang University recently developed a new technology called 「Transdermal delivery」 that can deliver drugs to the skin dermis without cell damage, and published a research paper (Subcytotoxic Transpidermal Delivery Using Low Intensity Cold Atmospheric Plasma) in the latest issue of Nature, a world-renowned international journal.
This study was conducted using a new low-density plasma medical device 'PlazMagik®, Agnes Medical' led by Professor Kim Bum-joon and Seok-joon of the Department of Dermatology at Chung-Ang University Hospital and Dr. Angaram of Harvard Medical School (author).
The research team evaluated the effectiveness of low-density plasma technology using human keratinocytes (HaCaT) and mouse skin models.
Unlike conventional plasma devices, the low-density plasma technology used in this study is designed to precisely control plasma density within a low output range, confirming that it can safely deliver materials to the dermis while maintaining high cell viability.
In addition, the analysis using fluorescence imaging and electron microscopy techniques confirmed the possibility that the material can be transmitted through both the paracellular route and the intracellular route.
As a result, the research team demonstrated in this study that low-density plasma technology can safely pass through the skin barrier and effectively deliver drugs to the dermis.
In particular, existing plasma devices caused thermal damage to the skin surface due to high-density plasma, but low-density plasma technology 'PlazMagik®' has been shown to provide effective treatment results such as drug delivery, whitening, and wrinkle improvement without side effects such as heat damage that is common in existing high-density plasma devices through low-density and precisely controlled output.
Professor Kim Bum-joon of the Department of Dermatology at Chung-Ang University Hospital said, "This is the third outcome of a series of studies conducted using "PlazMagik®" and previously published in SCI-class journals the effects of pigment deposition and wrinkle improvement caused by photoaging in a study using the same device."This study demonstrates that low-density plasma technology is also effective in drug delivery, further expanding the potential for clinical use of this technology."
Professor Seok-jun then said "This study is an important achievement of demonstrating that low-density plasma can be used to deliver drugs to the dermis without skin damage, and we expect this technology to be used as a drug delivery method as well as an innovative tool for drug delivery and regenerative treatment in various skin treatment fields in the future."
Meanwhile, the low-density plasma device 'PlazMagik®' was recently recognized for its safety and effectiveness by obtaining medical device licenses from the FDA (US Food and Drug Administration) and the Korean Ministry of Food and Drug Safety.
|
This article was translated by Naver AI translator.
